Phase 4 N=81 Artificial Tears, Tear Lipids and Tear Film Dynamics
Dry Eye
Primary: Tear Lipid Layer Thickness — 0.72; -7.58; 2.06; 1.41 nm
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=57 Dry Eye Symptom Relief Assessment With Use of TrueTear in a Controlled Adverse Environment
Dry Eye · Dry Eye Syndromes
Primary: Eye Dryness Score — 48 Score on Scale — p=0.0001
N/A N=32 Optive Brand For Day And Night Dry Eye Management
Dry Eye
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) Total Score — -12.85 Scores on a scale — p=.001
Phase 2 N=84 Dry Eye Disease Study With Brimonidine
Dry Eye
Primary: Tolerance of Test Substance Visual Analogue Scale (VAS) Score — 82.1; 87.0; 95.0; 91.1 score on a scale
N/A N=20 Acute Comfort of Lubricant Eye Drop FID 111421
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.7; 1.3 Units on a scale
Phase 4 N=20 Effects of Dry Eye Treatments on the Ocular Surface
Keratoconjunctivitis Sicca · Dry Eye Syndrome
Primary: Changes in Corneal Fluorescein Staining — 22.18; -3.35 units on a scale — p=<0.05
Phase 3 N=30 Platelet -Rich Plasma (PRP) Injection for the Treatment of Severe Dry Eye
Dry Eye · Sjogren Syndrome
Primary: Change From Baseline in Ocular Surface Staining — 1.2; 2.4 score on a scale
N/A N=20 Acute Comfort of Lubricant Eye Drops FID 112903
Dry Eye
Primary: Drop Comfort Upon Instillation — 1.1; 1.4 Units on a scale
N/A N=40 Tolerability, Safety and Efficacy of Lubricin Versus Sodium Hyaluronate Eye Drops in Patients With Moderate Dry Eye
Dry Eye Syndrome
Primary: Change From Baseline in Foreign Body Sensation, Burning/Stinging, Itching, Pain, Stick Feeling, Blurred Vision, Photophobia and Total Ocular Tolerability Score (VAS)…
Phase 4 N=51 Efficacy and Acceptability of Two Lubricant Eye Drops
Dry Eye Syndromes
Primary: Mean Frequency of Eye Drop Use Over 1 Week — 1.76; 1.66 Use per day
N/A N=139 Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye
Chalazion · Dry Eye Syndromes
Primary: Meibomian Gland Assessment (Total Meibomian Gland Secretion Score) — 6.3; 5.6; 14.3; 6.1 Scores on a scale
N/A N=20 Evaluation of Blink Tears and Systane Concomitant With Restasis for the Treatment of Dry Eye Symptoms
Dry Eye Syndrome
Primary: Change in Schirmer's Scores — -.30; -1.06 score on a scale
Phase 3 N=105 Efficacy and Safety of T2762 and Vismed® in Dry Eye Syndrome
Dry Eye Syndrome
Primary: Global Ocular Staining (With Oxford Scale - Ranges : 0-15) — -2.5; -2.7 score on a scale
Phase 3 N=236 Trial of CF101 to Treat Patients With Dry Eye Disease
Keratoconjunctivitis Sicca
Primary: Number of Subjects Who Achieved Complete Clearing of Corneal Staining (i.e., Total Corneal FS Score = 0) at Week 24 — 15; 13; 21; 61 participants
N/A N=47 Safety and Tolerability of Artificial Tears in Dry Eye Subjects
Dry Eye Syndrome
Primary: Tolerability Questionnaire Mean Scores at 1 Week — 70.1; 70.7; 57.3; 65.1 Scores on a scale
Phase 3 N=535 Dry Eye Assessment and Management Study
Dry Eye
Primary: Mean of Change From Baseline in Ocular Surface Disease Index (OSDI) Score at 6 and 12 Months — -13.9; -12.5 units on a scale — p=0.40
Phase 4 N=55 Clinical Evaluation of Two Marketed Artificial Tears in Non-contact Lens Wearing Patients
Visual Acuity
Primary: Ocular Comfort — 81.96; 82.49 Units on a scale
Phase 2 N=123 Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)
Dry Eye Disease
Primary: Mean Change in Schirmer's Test Score From Baseline to 84 Days — 10.8; 11.0; 6.0 mm
Phase 3 N=93 Comparison of the Efficacy and Safety of T2750 and Vismed® in the Treatment of Moderate to Severe Dry Eye Syndrome
Dry Eye Syndromes
Primary: Global Ocular Staining (With Oxford Scale - Ranges :0-15) — -1.8; -2 scores on a scale
Phase 3 N=154 Long Term Administration Study of OPC-12759 Ophthalmic Suspension
Dry Eye Syndromes
Primary: Change From Baseline (CFB) in Fluorescein Corneal Staining (FCS) Score — -2.2; -2.7; -4.1; -4.6 FCS score — p=<0.001
Phase 3 N=400 Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease
Dry Eye Disease (DED)
Primary: Change From Baseline in Total Staining Score at Day 90 in the Study Eye — -4.5; -3.4 score on a scale — p=0.0475
N/A N=200 Impairment of Reading Ability in Dry Eye Patients
Dry Eye Syndromes
Primary: Sustained Silent Reading Speed — 248.4; 270.3 words/minute
N/A N=12 Pilot Study of TearCare System - Long-Term Extension
Dry Eye Syndromes
Primary: Mean Change in Tear Break-Up Time From Extension Study Baseline to Month 1 — 12.4 seconds
N/A N=62 Efficacy, Safety of T2769 in Dry Eye Disease
Dry Eye Syndrome
Primary: Ocular Symptomatology — -55.9 units on a scale
N/A N=26 Mechanisms of Light-based Therapies for Dry Eye Disease
Dry Eye Syndromes · Meibomian Gland Dysfunction
Primary: Change From Baseline in Non-invasive Tear Break Up Time to the Final Follow-up 3 Months After Final Treatment Session — -2.61; -0.85 seconds
Phase 4 N=70 Study to Compare the Efficacy and Safety of Two Non-Preserved Artificial Tears for the Treatment of Dry Eye Signs and Symptoms
Dry Eye Syndromes
Primary: Change From Baseline in Ocular Surface Disease Index (OSDI) at Week 2 — 56.06; 54.292; -27.048; -28.303 Scores on a Scale
Phase 2 N=9 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye
Dry Eye · Sjogren's Syndrome · Graft vs. Host Disease
Primary: Safety — 0; 0 event
Phase 2 N=213 LME636 in the Relief of Persistent Ocular Discomfort in Subjects With Severe Dry Eye Disease
Dry Eye
Primary: Mean Change From Baseline in Global Ocular Discomfort Score at Day 71 — -7.9; -3.6 units on a scale
Phase 2 N=51 A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome
Dry Eye Syndromes
Primary: Efficacy of ADX-102 on Ocular Discomfort Using the Ora Calibra® Ocular Discomfort Scale. — -0.81; -0.75; -0.82 units on a scale
Phase 2 N=138 Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
Dry Eye Disease
Primary: Number of Subjects With Adverse Events — 13; 15; 10 Participants